Connor, Clark & Lunn Investment Management Ltd. Stoke Therapeutics, Inc. Transaction History

Connor, Clark & Lunn Investment Management Ltd.

$18.8 Billion
Q3 2024

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 10, 2023	SELL	$7.93 - $13.82 $50,434 - $87,895	-6,360 Reduced 12.25%	45,575 $484,000
Q1 2023 May 09, 2023	SELL	$7.65 - $10.38 $32,053 - $43,492	-4,190 Reduced 7.47%	51,935 $432,000
Q4 2022 Feb 10, 2023	BUY	$7.07 - $15.69 $112,321 - $249,267	15,887 Added 39.48%	56,125 $518,000
Q3 2022 Nov 10, 2022	BUY	$12.56 - $22.53 $289,847 - $519,924	23,077 Added 134.47%	40,238 $517,000
Q2 2022 Aug 05, 2022	BUY	$10.36 - $23.93 $53,913 - $124,531	5,204 Added 43.52%	17,161 $227,000
Q1 2022 May 12, 2022	BUY	$17.19 - $26.1 $44,040 - $66,868	2,562 Added 27.27%	11,957 $252,000
Q4 2021 Feb 10, 2022	BUY	$18.11 - $30.72 $170,143 - $288,614	9,395 New	9,395 $225,000

Others Institutions Holding STOK

# of Institutions

125

Shares Held

57.6M

Call Options Held

9.3K

Put Options Held

35.2K

View Full List

About Stoke Therapeutics, Inc.

Ticker STOK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,419,300
Market Cap $367M
Description
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output to design ASOs to precisely upregulate protein expression. I...

More about STOK

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Connor, Clark & Lunn Investment Management Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Connor, Clark & Lunn Investment Management Ltd. with notifications on news.

Account